

April 24, 2020

То	То	
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001	The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051	
Code: 540222	Code: LAURUSLABS	

Dear Sirs,

Sub: Board Meeting Intimation

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Thursday, April 30, 2020, *inter-alia*, to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31, 2020 and to recommend final Dividend, if any, on Equity Shares for the year ended March 31, 2020.

Further, the Company's trading window for dealing in securities by the Directors and Designated Persons has been closed from Wednesday, April 01, 2020, which was already intimated on March 31, 2020, and shall continue to remain closed till Saturday, May 02, 2020 (both days inclusive).

This is for your information and records.

Thanking you,

Active Pharmaceutical Ingredients & Intermediates

Yours sincerely, For Laurus Labs Limited AB.C lyderabad G. Venkateswar Reddy **Company Secretary** 

Finished Dosage Forms

Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518 T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

AURUS Generics LAURUS Generics LAURUS Synthesis LAURUS Ingredients

Contract Development & Manufacturing Services

Specialty Ingredients for Nutraceutical & Allied Industry